These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24212944)

  • 21. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
    Olmos D; Tan DS; Jones RL; Judson IR
    Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
    Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
    Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.
    Ulanet DB; Ludwig DL; Kahn CR; Hanahan D
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10791-8. PubMed ID: 20457905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the pathway to insulin-like growth factor system targeting in cancer.
    Rosenzweig SA; Atreya HS
    Biochem Pharmacol; 2010 Oct; 80(8):1115-24. PubMed ID: 20599789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.
    Jin M; Buck E; Mulvihill MJ
    Oncol Rev; 2013 Apr; 7(1):e3. PubMed ID: 25992224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
    Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
    Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
    Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
    Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells.
    Liu R; Tang W; Han X; Geng R; Wang C; Zhang Z
    Oncol Lett; 2018 Nov; 16(5):5983-5991. PubMed ID: 30333869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
    Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
    J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
    Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
    Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.
    Negi A; Ramarao P; Kumar R
    Mini Rev Med Chem; 2013 Apr; 13(5):653-81. PubMed ID: 23373648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
    Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
    Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IR-A/IGF-1R-mediated signals promote epithelial-mesenchymal transition of endometrial carcinoma cells by activating PI3K/AKT and ERK pathways.
    Wang C; Su K; Zhang Y; Zhang W; Zhao Q; Chu D; Guo R
    Cancer Biol Ther; 2019; 20(3):295-306. PubMed ID: 30426831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microarray analysis of insulin and insulin-like growth factor-1 (IGF-1) receptor signaling reveals the selective up-regulation of the mitogen heparin-binding EGF-like growth factor by IGF-1.
    Mulligan C; Rochford J; Denyer G; Stephens R; Yeo G; Freeman T; Siddle K; O'Rahilly S
    J Biol Chem; 2002 Nov; 277(45):42480-7. PubMed ID: 12213819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.